The daily pill delivers great results – without a needle, a sharps bin or a single moment of dread.
Weight loss medication that feels less like medication and more like something you already do every day.
The pill looks like any other vitamin, private by design. Weight loss is nobody's business but yours – the pill helps it stay that way.
Orforglipron, brand name Foundayo, is now approved in the UK. It is made by Eli Lilly, the same company that makes Mounjaro, but it is not a Mounjaro pill. Unlike other oral GLP-1s, it can be taken at any time of day, with or without food.
Foundayo isn't in pharmacies just yet, but stock is expected soon. Join the waitlist now to be one of the first to access it through Voy.
The world of weight loss treatment is evolving fast. For years, the most effective options have required weekly injections. That's starting to change.
The Wegovy pill became the first oral GLP-1 weight loss medicine of its kind when it launched in the US in January 2026, before receiving MHRA approval in the UK in June 2026. Orforglipron arrived in the US shortly after, approved in April 2026 under the brand name Foundayo, and has now received MHRA approval in the UK too.
In clinical trials, orforglipron helped people lose up to 12.4% of their starting weight over 72 weeks, with promising results in both weight loss and blood sugar control.
Here's what we know so far.
Orforglipron, sold as Foundayo, is a once-daily GLP-1 weight loss pill. Like Wegovy injections and Saxenda, it mimics a natural hormone called GLP-1, which reduces hunger, curbs cravings, and helps you feel fuller for longer.
Unlike other GLP-1 medications, orforglipron is a non-peptide small molecule. This means Foundayo can be taken at any time of day, with or without food. The Wegovy pill and Rybelsus, by contrast, need to be taken on an empty stomach with a 30-minute wait before eating or drinking.
Although orforglipron and Mounjaro are both made by Eli Lilly, they are completely different medicines. Mounjaro contains tirzepatide, which works on two hormones (GLP-1 and GIP) and is given as a weekly injection. Orforglipron targets GLP-1 only and comes as a daily tablet. For a full comparison, see our guide on orforglipron vs tirzepatide.
Like all GLP-1 medications, orforglipron works best alongside a reduced-calorie diet and regular physical activity.
FYI: Ozempic contains the same active ingredient as Wegovy (semaglutide) but is licensed for type 2 diabetes rather than weight loss.
Orforglipron weight loss without type 2 diabetes:
Over 3,100 adults with obesity or overweight took orforglipron for 72 weeks. People on the maximum 17.2mg dose lost an average of 12.4% of their body weight, compared to 0.9% with placebo. Results were dose-dependent, with higher doses producing greater weight loss.
Orforglipron weight loss with type 2 diabetes:
People living with both obesity and type 2 diabetes took orforglipron for 72 weeks. Those on the maximum 17.2mg dose lost an average of 10.5% of their body weight, compared to 2.2% with placebo.
Oral semaglutide is orforglipron's closest competitor. There are currently two oral semaglutide options:
Rybelsus: licensed in the UK for type 2 diabetes
Wegovy pill: licensed in the UK for weight loss.
People taking the Wegovy pill (25mg) lost 16.6% of their body weight over 64 weeks among those who completed the full course of treatment.
Both the Wegovy pill and orforglipron are once-daily oral GLP-1 medicines, now approved in the UK. The Wegovy pill contains semaglutide, the same active ingredient as Wegovy injections, and unlike orforglipron, it must be taken on an empty stomach each morning with a 30-minute wait before eating or drinking. Orforglipron is also licensed for type 2 diabetes, whereas the Wegovy pill is licensed for weight loss only.
At its highest dose (25mg), the Wegovy pill led to an average weight loss of 16.6%, while orforglipron at its highest dose (17.2mg) led to an average of 12.4%. These figures come from separate trials, so they aren't a direct comparison, but they give a sense of how each performs at the dose people would actually be prescribed.
Take a quick eligibility quiz to explore your options and see how we can support you.
Orforglipron shows promising results, but injectable GLP-1 medications tend to produce greater weight loss at their highest doses:
So while orforglipron doesn't quite match the top-performing injectables, it's a step forward for people who prefer not to inject. For a detailed comparison with Mounjaro specifically, see our guide on orforglipron vs tirzepatide.
Orlistat (sold as Orlos) is a weight loss tablet that has been available in the UK for many years. It works differently from GLP-1 medications, reducing the amount of fat your gut absorbs from food rather than suppressing appetite.
Orforglipron appears significantly more effective. Around 1 in 5 people taking orlistat lose at least 10% of their body weight after a year, compared to 60% of people on orforglipron at the highest trial dose over 72 weeks.
Orforglipron is taken as a once-daily tablet, starting at a low dose and gradually increasing. The approved dosing schedule for Foundayo goes from a starting dose of 0.8mg up to a maximum of 17.2mg.
Your prescriber will move you up to the next dose after at least 30 days, until you find the dose that works best for you. Not everyone needs to reach the maximum 17.2mg dose, and some may stay on a lower dose long-term if they're seeing results and tolerating it well.
Orforglipron is taken once a day, with or without food, at any time of day. Swallow the tablet whole, without breaking, crushing, or chewing it.If you miss a dose, take it as soon as you remember. Don't take two doses in the same day.
If you miss orforglipron for 7 or more days in a row, speak to your prescriber before restarting treatment.
Orforglipron tablets don't need any special temperature storage conditions, but they are light-sensitive, so keep them in their original packaging. Keep out of reach of children.
Orforglipron side effects were mostly mild to moderate and consistent with other GLP-1 medications. The most commonly reported in trials were:
These were most common during dose escalation and generally eased over time.
Like other GLP-1 receptor agonists, orforglipron has been associated with a modest increase in resting heart rate. In phase 3 trials, people taking Foundayo experienced an average increase of 4 to 5 beats per minute, compared to less than 1 beat per minute with placebo. This is not usually clinically significant in otherwise healthy people, but worth discussing with your clinician if you have a heart condition or take any medications that affect your heart rate.
There is also a small risk of gallbladder problems, including gallstones, which has been seen with GLP-1 medicines generally. Tell your clinician if you develop upper abdominal pain.
Early data also suggests orforglipron may cause fewer gut-related side effects than Mounjaro, which works on two hormones (GLP-1 and GIP) rather than one. That dual action is what makes Mounjaro particularly effective for weight loss, but it may also contribute to more side effects.
Orforglipron isn't suitable for everyone. Based on current prescribing information for Foundayo, the main contraindications and warnings are:
Don't take orforglipron if you:
Talk to your prescriber first if you:
Yes. The UK is the first country in Europe to approve orforglipron for type 2 diabetes as well as weight management, so it can now be prescribed to help with blood sugar control too.
In people with both obesity and type 2 diabetes, 75% of those taking the highest trial dose reached an HbA1c of 6.5% or below, the level used to diagnose type 2 diabetes. Blood sugar levels fell by an average of 1.3% to 1.8% across doses.
In a head-to-head trial, orforglipron lowered HbA1c more than Rybelsus, the only oral GLP-1 currently licensed for type 2 diabetes in the UK.
Beyond weight loss, orforglipron has shown a range of other health improvements across trials. People taking the medication saw reductions in blood pressure, improvements in cholesterol, lower triglyceride levels, and meaningful reductions in waist circumference, all markers of cardiovascular and metabolic health.
A separate analysis also found that levels of an inflammation marker called high-sensitivity C-reactive protein (hsCRP) fell by 47.7% at the highest trial dose. That matters because chronic inflammation is linked to heart disease, type 2 diabetes, and other long-term conditions.
These findings suggest Foundayo may offer broader benefits for heart and metabolic health, but longer-term outcome trials are still ongoing.
Many people who reach their goal weight on Wegovy or Mounjaro wonder what comes next, and whether switching to a tablet could help them maintain their results.
The ATTAIN-MAINTAIN trial followed people who had lost weight on Wegovy or Zepbound (the US version of Mounjaro for weight loss) over 72 weeks, before switching them to orforglipron. Those who switched from Wegovy had lost around 18kg and gained back less than 1kg after switching. Those who switched from Zepbound had lost around 25kg and gained back 5kg.
This is promising early evidence for orforglipron as a maintenance option.
With Voy, Foundayo pricing starts from £69 a month for the lowest dose on a 6-month plan. Longer plans work out cheaper per month, and prices rise as your dose increases, unless you choose to stay on a lower one. All new customers receive a discount on their first order.
Disclaimer
At Voy, we ensure that everything you read in our blog is medically reviewed and approved. However, the information provided is not meant to replace professional medical advice, diagnosis, or treatment. It should not be relied upon for specific medical advice.
Yes, orforglipron, sold as Foundayo, was approved in the UK on 10 August 2026 for both weight management and type 2 diabetes, making the UK the first country in Europe to authorise it. It isn't in pharmacies just yet, so join the waitlist to find out as soon as it's available to prescribe through Voy
Orforglipron is a once-daily pill for weight loss, made by Eli Lilly and sold under the brand name Foundayo. In trials, people lost up to 12.4% of their body weight over 72 weeks. Unlike the Wegovy pill, it can be taken at any time of day, with or without food. It's now approved in the UK, and you can join the waitlist to find out as soon as it's available through Voy.
No. Both are made by Eli Lilly, but they are completely different medicines. Mounjaro contains tirzepatide, which works on two hormones (GLP-1 and GIP) and is given as a weekly injection. There is no Mounjaro pill. Orforglipron works on GLP-1 only and comes as a once-daily tablet. They have different active ingredients, different mechanisms, and different dosing schedules.
Based on phase 3 trial data involving thousands of participants, orforglipron has a similar safety profile to other GLP-1 medications like Wegovy and Mounjaro. Side effects were mostly mild to moderate and gut-related.
No. Both work by mimicking the GLP-1 hormone to reduce appetite, but they're different substances. Semaglutide is used in Wegovy injections, Ozempic, the Wegovy pill and Rybelsus, while orforglipron is a different molecule. The key practical difference is that orforglipron can be taken at any time of day, whereas the Wegovy pill and Rybelsus must be taken on an empty stomach with a 30-minute wait before eating or drinking.
Orforglipron (Foundayo) is now approved in the UK. It's not yet in pharmacies, since stock typically takes a little while to arrive after any drug approval. Join the waitlist and we'll email you the moment it's ready through Voy.
You can buy orforglipron through private prescription providers like Voy. It's sold under the brand name Foundayo, and it's now approved in the UK, but stock hasn't arrived yet. Join the waitlist and we'll let you know as soon as it's ready. NHS availability will take longer.
With Voy, Foundayo pricing starts from £69 a month for the lowest dose on a 6-month plan. Longer plans work out cheaper per month, and prices rise as your dose increases, unless you choose to stay on a lower one. All new customers receive a discount on their first order.
Mounjaro currently produces greater weight loss in trials, with up to 22.5% at its highest dose compared to 12.4% with orforglipron. Mounjaro is a weekly injection whereas orforglipron is a once-daily tablet, which may suit people who prefer not to inject. For a detailed comparison, see our guide on orforglipron vs tirzepatide.
Not yet. Even though Foundayo is approved in the UK, it still needs a separate review before it can be prescribed on the NHS, which usually takes longer than private availability.
Based on your health history, BMI and personal goals, we’ll recommend the one that’s right for you.
Lose up to 20.7% body weight
Lose up to 22.5% body weight
Lose up to 8.5% body weight
¹ Dutta, Deep, et al. "Orforglipron, a Novel Non-Peptide Oral Daily Glucagon-Like Peptide-1 Receptor Agonist as an Anti-Obesity Medicine: A Systematic Review and Meta-Analysis." Obesity Science and Practice, vol. 10, no. 2, 26 Feb. 2024, e743, doi.org/10.1002/osp4.743.
² Eli Lilly and Company. "FDA Approves Lilly's Foundayo™ (Orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions." Eli Lilly and Company Investor Relations, 1 Apr. 2026, investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill.
³ Eli Lilly and Company. "How to Take Foundayo™ (Orforglipron)." Foundayo, 2026, foundayo.lilly.com/how-to-take. Accessed 19 May 2026.
⁴ Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Delivered Superior Blood Sugar Control and Weight Loss Compared to Oral Semaglutide in Head-to-Head Type 2 Diabetes Trial Published in The Lancet." Eli Lilly and Company, 26 Feb. 2026, lilly.gcs-web.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar.
⁵ Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Delivers Weight Loss of up to an Average of 27.3 lbs in First of Two Pivotal Phase 3 Trials in Adults with Obesity." Eli Lilly and Company Investor Relations, 7 Aug. 2025, investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273.
⁶ Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Demonstrated Meaningful Weight Reduction and Improved Cardiometabolic Health in Adults with Type 2 Diabetes." Eli Lilly and Company Investor Relations, 16 Sept. 2025, investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-meaningful-weight.
⁷ Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Demonstrated Statistically Significant Efficacy Results and Safety Profile Consistent with Injectable GLP-1 Class in Successful Phase 3 Trial." Eli Lilly and Company Investor Relations, 17 Apr. 2025, investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-demonstrated-statistically.
⁸ Eli Lilly and Company. "Lilly's Oral GLP-1, Orforglipron, Is Successful in Third Phase 3 Trial, Triggering Global Regulatory Submissions This Year for the Treatment of Obesity." Eli Lilly and Company Investor Relations, 26 Aug. 2025, investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-successful-third-phase-3-trial.
⁹ Eli Lilly and Company. "Lilly's Orforglipron Helped People Maintain Weight Loss After Switching from Injectable Incretins to Oral GLP-1 Therapy in First-of-Its-Kind Phase 3 Trial." Eli Lilly and Company Investor Relations, 18 Dec. 2025, investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after.
¹⁰ Eli Lilly and Company. "Lilly's SURMOUNT-1 Results Published in The New England Journal of Medicine." Eli Lilly and Company Investor Relations, 4 June 2022, investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicine.
¹¹ Eli Lilly and Company. "What Is Foundayo™ (Orforglipron)?" Foundayo, 2026, foundayo.lilly.com/what-is-foundayo. Accessed 19 May 2026.
¹² "Foundayo (Orforglipron) Tablets: Prescribing Information." US Food and Drug Administration, Eli Lilly and Company, 2026, www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934Orig1s000lbl.pdf.
¹³ Medicines and Healthcare products Regulatory Agency. "UK First in Europe to Authorise Orforglipron for Weight Management and Type 2 Diabetes." GOV.UK, 10 Aug. 2026, www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes.
¹⁴ "Mounjaro (Tirzepatide) Injection: Prescribing Information." US Food and Drug Administration, Eli Lilly and Company, 2022, www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf.
¹⁵ Novo Nordisk Inc. "Novo Nordisk's Wegovy® Pill, the First and Only Oral GLP-1 for Weight Loss in Adults, Now Broadly Available Across America." PR Newswire, 5 Jan. 2026, www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html.
¹⁶ Novo Nordisk. "Taking Wegovy® Pill." Wegovy, 2026, www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html. Accessed 19 May 2026.
¹⁷ "Saxenda (Liraglutide) Injection: Prescribing Information." US Food and Drug Administration, Novo Nordisk, Apr. 2023, www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf.
¹⁸ Wharton, Sean, et al. "Efficacy and Safety of Semaglutide 7.2 mg in Obesity: The STEP UP Trial." Presented at the American Diabetes Association 85th Scientific Sessions, 20-23 June 2025, Chicago, IL. Novo Nordisk Science Hub, sciencehub.novonordisk.com/content/dam/sciencehub/global/en/congresses-and-scientific-publications/congresses/ada2025/Wharton/documents/ADA25_STEP_UP_ePoster_slides.pdf.
¹⁹ Wharton, Sean, et al. "Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment." New England Journal of Medicine, vol. 393, no. 18, 6 Nov. 2025, pp. 1796-1806, https://doi.org/10.1056/NEJMoa2511774.
Join the priority list for early access updates, secure sign-up and expert support ahead of launch.
